Francisco José Márquez-Malaver

Francisco José Márquez-Malaver

Auto-generated profile, based on publicly available information

Francisco José Márquez-Malaver

Department of Hematology of the University Hospital Virgen del Rocío, Instituto de Biomedicina (IBIS/CSIC/CIBERONC, CB16/12/00480), Universidad de Sevilla, Seville, Spain

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2019 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
O(On Behalf Of The Grupo Español de Trasplante Hematopoyético (Geth)
On Behalf Of The Grupo Español de Trasplante Hematopoyético (Geth)
VGVirginia Escamilla Gómez
Virginia Escamilla Gómez
VGValentín García Gutiérrez
Valentín García Gutiérrez
LCLucía López Corral
Lucía López Corral
IGIrene García-Cadenas
Irene García-Cadenas
JPJose A Perez-Simon
Jose A Perez-Simon
Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids. Unfortunately, second-line treatment for both acute and chronic graft-versus-host disease, remains a challenge. Ruxolitinib has been shown as an effective and safe treatment option for these patients. Seventy-nine patients received ruxolitinib and were evaluated in this retrospective and multicenter study. Twenty-three patients received ruxolitinib for refractory acute graft-versus-host disease after a median of 3 (range 1–5) previous lines of therapy. Overall response rate was 69.5% (16/23) which was obtained after a median of 2 weeks of treatment, and 21.7% (5/23) reached complete remission. Fifty-six patients were evaluated for refractory chronic graft-versus-host disease. The median number of previous lines of therapy was 3 (range 1–10). Overall response rate was 57.1% (32/56) with 3.5% (2/56) obtaining complete remission after a median of 4 weeks. Tapering of corticosteroids was possible in both acute (17/23, 73%) and chronic graft-versus-host disease (32/56, 57.1%) groups. Overall survival was 47% (CI: 23–67%) at 6 months for patients with aGVHD (62 vs 28% in responders vs non-responders) and 81% (CI: 63–89%) at 1 year for patients with cGVHD (83 vs 76% in responders vs non-responders). Ruxolitinib in the real life setting is an effective and safe treatment option for GVHD, with an ORR of 69.5% and 57.1% for refractory acute and chronic graft-versus-host disease, respectively, in heavily pretreated patients.

1 April 2015 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
JFJose F. Falantes
Jose F. Falantes
PTPablo Trujillo
Pablo Trujillo
JPJose I. Piruat
Jose I. Piruat
CCCristina Calderón
Cristina Calderón
FMFrancisco J. Márquez-Malaver
Francisco J. Márquez-Malaver
JPJose A. Pérez-Simón
Jose A. Pérez-Simón

30 November 2016 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
TCTeresa Caballero-Velázquez
Teresa Caballero-Velázquez
IMIsabel Montero
Isabel Montero
FSFermin Sanchez-Guijo
Fermin Sanchez-Guijo
RPRocío Parody
Rocío Parody
RSRaquel Saldaña
Raquel Saldaña
JPJose A Perez-Simon
Jose A Perez-Simon
Purpose: We describe the results of a prospective multicenter phase I/II trial evaluating the impact of the use of vitamin D (VitD) from day −5 to +100 on the outcome of patients undergoing allogeneic transplantation (EudraCT: 2010-023279-25; ClinicalTrials.gov: NCT02600988).Experimental Design: A total of 150 patients were included in three consecutive cohorts of 50 patients each group: control group (CG, not receive VitD); low-dose group (LdD, received 1,000 IU VitD daily); and high-dose group (HdD, 5,000 IU VitD daily). We measured levels of VitD, cytokines, and immune subpopulations after transplantation.Results: No significant differences were observed in terms of cumulative incidence of overall and grades 2–4 acute GVHD in terms of relapse, nonrelapse mortality, and overall survival. However, a significantly lower cumulative incidence of both overall and moderate plus severe chronic GVHD (cGVHD) at 1 year was observed in LdD (37.5% and 19.5%, respectively) and HdD (42.4% and 27%, respectively) as compared with CG (67.5% and 44.7%, respectively; P < 0.05). In multivariable analysis, treatment with VitD significantly decreased the risk of both overall (for LdD: HR = 0.31, P = 0.002; for HdD: HR = 0.36, P = 0.006) and moderate plus severe cGVHD (for LdD: HR = 0.22, P = 0.001; for HdD: HR = 0.33, P = 0.01). VitD modified the immune response, decreasing the number of B cells and naïve CD8 T cells, with a lower expression of CD40L.Conclusions: This is the first prospective trial that analyzes the effect of VitD postransplant. We observed a significantly lower incidence of cGVHD among patients receiving VitD. Interestingly, VitD modified the immune response after allo-SCT. Clin Cancer Res; 22(23); 5673–81. ©2016 AACR.

1 February 2014 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
JFJose F. Falantes
Jose F. Falantes
CCCristina Calderón
Cristina Calderón
FMFrancisco J. Márquez-Malaver
Francisco J. Márquez-Malaver
MAManuela Aguilar-Guisado
Manuela Aguilar-Guisado
AMAlmudena Martín-Peña
Almudena Martín-Peña
IEIldefonso Espigado
Ildefonso Espigado

12 October 2012 in Haematologica
Verified
Journal Article
Closed access
PDF file
JPJose A Perez-Simon
Jose A Perez-Simon
RMR. Martino
R. Martino
RPR. Parody
R. Parody
MCM. Cabrero
M. Cabrero
LLL. Lopez-Corral
L. Lopez-Corral
DCD. Caballero
D. Caballero
Different types of graft-versus-host disease prophylaxis have been proposed in the setting of reduced intensity and non-myeloablative allogeneic stem cell transplantation. An alternative combination with sirolimus and tacrolimus has recently been tested although comparative studies against the classical combination of a calcineurin inhibitor and mycophenolate mofetil or methotrexate are lacking. We describe the results of a prospective, multicenter trial using sirolimus + tacrolimus as immunoprophylaxis, and compare this approach with our previous experience using cyclosporine + mycophenolate in the setting of unrelated donor transplantation setting after reduced-intensity conditioning. Forty-five patients received cyclosporine + mycophenolate between 2002 and mid-2007, while the subsequent 50 patients, who were transplanted from late 2007, were given sirolimus + tacrolimus. No significant differences were observed in terms of hematopoietic recovery or acute graft-versus-host disease overall, although gastrointestinal acute graft-versus-host disease grade ≥2 was more common in the cyclosporine + mycophenolate group (55% versus 21%, respectively, P=0.003). The 1-year cumulative incidence of chronic graft-versus-host disease was 50% versus 90% for the patients treated with the sirolimus- versus cyclosporine-based regimen, respectively (P<0.001), while the incidence of extensive chronic disease was 27% versus 49%, respectively (P=0.043). The 2-year non-relapse mortality rate was 18% versus 38% for patients receiving the sirolimus- versus the cyclosporine-based regimen, respectively (P=0.02). The event-free survival and overall survival at 2 years were 53% versus 29% (P=0.028) and 70% versus 45% (P=0.018) among patients receiving the sirolimus- versus the cyclosporine-based regimen, respectively. In conclusion, in the setting of reduced intensity transplantation from an unrelated donor, promising results can be achieved with the combination of sirolimus + tacrolimus, due to a lower risk of chronic graft-versus-host disease and non-relapse mortality, which translates into better event-free and overall survival rates, in comparison with those achieved with cyclosporine + mycophenolate. This trial was registered at www.clinicaltrials.gov as 2007-006416-32 by GEL-TAMO/GETH.

24 May 2013 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
RPRocío Parody
Rocío Parody
DCDolores Caballero
Dolores Caballero
FMFrancisco J. Márquez‐Malaver
Francisco J. Márquez‐Malaver
LVLourdes Vázquez
Lourdes Vázquez
RSRaquel Saldaña
Raquel Saldaña
JPJose A. Pérez‐Simón
Jose A. Pérez‐Simón